These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10502617)

  • 1. A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy.
    Molpeceres J; Chacón M; Guzmán M; Berges L; del Rosario Aberturas M
    Int J Pharm; 1999 Sep; 187(1):101-13. PubMed ID: 10502617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation.
    Meier-Kriesche HU; Kaplan B; Brannan P; Kahan BD; Portman RJ
    Ther Drug Monit; 1998 Aug; 20(4):401-7. PubMed ID: 9712465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats.
    Varela MC; Guzmán M; Molpeceres J; del Rosario Aberturas M; Rodríguez-Puyol D; Rodríguez-Puyol M
    Eur J Pharm Sci; 2001 Feb; 12(4):471-8. PubMed ID: 11231114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P; Niese D
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients.
    Balram C; Sivathasan C; Cheung YB; Tan SB; Tan YS
    J Heart Lung Transplant; 2002 Sep; 21(9):1016-21. PubMed ID: 12231373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats.
    Yang ZQ; Xu J; Pan P; Zhang XN
    Pharmazie; 2009 Jan; 64(1):26-31. PubMed ID: 19216227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients.
    Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R
    Pediatr Transplant; 1999 Nov; 3(4):282-7. PubMed ID: 10562972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients.
    Kabasakul SC; Clarke M; Kane H; Karsten J; Clark G
    Pediatr Nephrol; 1997 Jun; 11(3):318-21. PubMed ID: 9203180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration.
    Gaspari F; Anedda MF; Signorini O; Remuzzi G; Perico N
    J Am Soc Nephrol; 1997 Apr; 8(4):647-52. PubMed ID: 10495795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients.
    Meier-Kriesche HU; Alloway R; Gaber AO; Canafax DM; Kaplan B
    J Clin Pharmacol; 1999 Feb; 39(2):166-71. PubMed ID: 11563409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure.
    Primmett DR; Levine M; Kovarik JM; Mueller EA; Keown PA
    Ther Drug Monit; 1998 Jun; 20(3):276-83. PubMed ID: 9631924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.
    Kees F; Bucher M; Schweda F; Gschaidmeier H; Burhenne J; Mikus G; Faerber L
    Ther Drug Monit; 2006 Jun; 28(3):312-20. PubMed ID: 16778713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalence of cyclosporine blood level assays in patients receiving cyclosporine microemulsion or cyclosporine. The Sandoz Neoral Study Group N103.
    Pescovitz MD; Wong RL; Choc MG; Chang CT
    Clin Transplant; 1997 Oct; 11(5 Pt 1):442-5. PubMed ID: 9361938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group.
    Hoyer PF
    Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of Sandimmun® versus Sandimmun Neoral®: a meta-analysis of published studies.
    Colombo D; Egan CG
    Int J Immunopathol Pharmacol; 2010; 23(4):1177-83. PubMed ID: 21244766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients.
    Tokui K; Kimata T; Uchida K; Yuasa H; Hayashi Y; Itatsu T; Nabeshima T
    Ther Drug Monit; 2004 Jun; 26(3):287-94. PubMed ID: 15167630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Orally Administered Poly(Ethylene Oxide)-block-Poly(ε-Caprolactone) Micelles of Cyclosporine A in Rats: Comparison with Neoral®.
    Binkhathlan Z; Ali R; Qamar W; Lavasanifar A
    J Pharm Pharm Sci; 2018; 21(1s):192s-199s. PubMed ID: 30139426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.